How to buy Harpoon Therapeutics stock (HARP)

Harpoon Therapeutics is a biotechnology business based in the US. Harpoon Therapeutics shares (HARP) are listed on the NASDAQ and all prices are listed in US Dollars. Harpoon Therapeutics employs 53 staff and has a trailing 12-month revenue of around $37.3 million.

Our top picks for where to buy Harpoon Therapeutics stock

Buy Harpoon Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Harpoon Therapeutics stock price (NASDAQ: HARP)

Use our graph to track the performance of HARP stocks over time.

Harpoon Therapeutics shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$10.23 - $23.21
50-day moving average more info button	$21.62
200-day moving average more info button	$11.15
Wall St. target price	$24.79
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-8.62

Is it a good time to buy Harpoon Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Harpoon Therapeutics financials

Revenue TTM	$37.3 million
Gross profit TTM	$-49,478,000
Return on assets TTM	-35.66%
Return on equity TTM	-284.32%
Profit margin	-81.67%
Book value	$1.11
Market Capitalization more info button	$492.3 million

TTM: trailing 12 months

Harpoon Therapeutics share dividends

We're not expecting Harpoon Therapeutics to pay a dividend over the next 12 months.

Have Harpoon Therapeutics's shares ever split?

Harpoon Therapeutics's shares were split on a 1:10 basis on 4 September 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harpoon Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Harpoon Therapeutics shares which in turn could have impacted Harpoon Therapeutics's share price.

Harpoon Therapeutics share price volatility

Over the last 12 months, Harpoon Therapeutics's shares have ranged in value from as little as $10.23 up to $23.21. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harpoon Therapeutics's is 2.098. This would suggest that Harpoon Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Harpoon Therapeutics overview

Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Frequently asked questions

null
What percentage of Harpoon Therapeutics is owned by insiders or institutions?
Currently 0.346% of Harpoon Therapeutics shares are held by insiders and 82.854% by institutions. How many people work for Harpoon Therapeutics?
Latest data suggests 53 work at Harpoon Therapeutics. When does the fiscal year end for Harpoon Therapeutics?
Harpoon Therapeutics's fiscal year ends in December. Where is Harpoon Therapeutics based?
Harpoon Therapeutics's address is: 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Harpoon Therapeutics's ISIN number?
Harpoon Therapeutics's international securities identification number is: US41358P1066 What is Harpoon Therapeutics's CUSIP number?
Harpoon Therapeutics's Committee on Uniform Securities Identification Procedures number is: 41358P106